

MACROGENICS INC

Form 10-Q

May 01, 2019

FALSEMarch 31, 20192019Q1Large Accelerated FilerFALSEFALSEMACROGENICS

INC0001125345--12-310.010.01125,000,000125,000,00048,805,00842,353,301P5YP5Y73.774.468712.32.62.42.8000112534

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 10-Q**

**QUARTERLY  
REPORT  
PURSUANT  
TO SECTION  
13 OR 15(d) OF  
THE  
SECURITIES  
EXCHANGE  
ACT OF 1934**

**For the quarterly period ended March 31, 2019  
OR**

**TRANSITION  
REPORT  
PURSUANT  
TO SECTION  
13 OR 15(d) OF  
THE  
SECURITIES  
EXCHANGE  
ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission File Number: 001-36112**

**MACROGENICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware 06-1591613**

**(State or other  
jurisdiction of  
incorporation  
or  
organization) (I.R.S.  
Employer  
Identification  
No.)**

**9704 Medical  
Center Drive 20850  
Rockville,  
Maryland**

**(Zip code)**

(Address of principal executive offices)

301-251-5172

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "accelerated filer," "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer      Accelerated filer

Non-accelerated filer      Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of April 26, 2019, the number of outstanding shares of the registrant's common stock, par value \$0.01 per share, was 48,805,620 shares.

---

**TABLE OF CONTENTS**

**PART I. FINANCIAL INFORMATION**

- Item 1. Financial Statements
- Consolidated Balance Sheets at March 31, 2019 (unaudited) and December 31, 2018
- Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2019 and March 31, 2018 (unaudited)
- Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2019 and March 31, 2018 (unaudited)
- Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and March 31, 2018 (unaudited)
- Notes to Consolidated Financial Statements (unaudited)
- Management's Discussion and Analysis of Financial Condition and Results of Operations
- Item 2. Quantitative and Qualitative
- Item 3. Quantitative and Qualitative

Disclosures about  
Market Risk

Item 4. Controls and  
Procedures

**PART II. OTHER  
INFORMATION**

Item 1A. Risk Factors

Item 6. Exhibits

Signatures

---

## **FORWARD-LOOKING STATEMENTS**

This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.

All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:

- our plans to develop and commercialize our product candidates;
- the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings made;
- the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
- our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
- our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;
- the potential benefits and future operation of our existing collaborations;
- our ability to recover the investment in our manufacturing capabilities;
- the rate and degree of market acceptance and clinical utility of our products;
- our commercialization, marketing and manufacturing capabilities and strategy;
- significant competition in our industry;
- costs of litigation and the failure to successfully defend lawsuits and other claims against us;
- economic, political and other risks associated with our international operations;
- our ability to receive research funding and achieve anticipated milestones under our collaborations;
- our ability to protect and enforce patents and other intellectual property;
- costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;
- loss or retirement of key members of management;
- failure to successfully execute our growth strategy, including any delays in our planned future growth; and
- our failure to maintain effective internal controls.

Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.

---

**PART I. FINANCIAL INFORMATION**  
**ITEM 1. FINANCIAL STATEMENTS**

**MACROGENICS, INC.**  
**CONSOLIDATED BALANCE SHEETS**  
**(in thousands, except share and per share data)**

	<b>March 31, 2019</b>		<b>December 31, 2018</b>
	<b>(unaudited)</b>		
<b>Assets</b>			
Current assets:			
Cash and cash equivalents	\$ 238,641	\$	220,128
Marketable securities	81,750		12,735
Accounts receivable	6,115		29,583
Prepaid expenses	8,309		6,406
Other current assets	218		272
Total current assets	335,033		269,124
Property, equipment and software, net	54,818		56,712
Other assets	24,787		6,294
Total assets	\$ 414,638	\$	332,130
<b>Liabilities and stockholders' equity</b>			
Current liabilities:			
Accounts payable	\$ 925	\$	4,005
Accrued expenses	28,852		33,021
Deferred revenue	18,085		21,721
Deferred rent	—		1,018
Lease liabilities	3,734		—
Other liabilities	175		175
Total current liabilities	51,771		59,940
Deferred revenue, net of	17,207		19,001

current portion			
Lease liabilities, net of current portion	25,043		—
Deferred rent, net of current portion	—		10,312
Total liabilities	94,021		89,253
Stockholders' equity:			
Common stock, \$0.01 par value -- 125,000,000 shares authorized, 48,805,008 and 42,353,301 shares outstanding at March 31, 2019 and December 31, 2018, respectively	488		424
Additional paid-in capital	855,417		732,727
Accumulated other comprehensive loss	—		(3)
Accumulated deficit	(535,288)		(490,271)
Total stockholders' equity	320,617		242,877
Total liabilities and stockholders' equity		414,638	\$ 332,130

*See accompanying notes.*

1

---

**MACROGENICS, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**  
**(unaudited)**  
**(in thousands, except share and per share data)**

	<b>Three Months Ended March 31,</b>	
	<b>2019</b>	<b>2018</b>
Revenues:		
Revenue from collaborative agreements	\$ 9,497	\$ 4,501
Revenue from government agreements	165	194
Total revenues	9,662	4,695
Costs and expenses:		
Research and development	47,060	45,670
General and administrative	10,219	9,235
Total costs and expenses	57,279	54,905
Loss from operations	(47,617)	(50,210)
Other income	2,600	674
Net loss	(45,017)	(49,536)
Other comprehensive loss:		
Unrealized gain on investments	3	39
Comprehensive loss	\$ (45,014)	\$ (49,497)
Basic and diluted net loss per common share	\$ (0.99)	\$ (1.34)
Basic and diluted weighted average common shares outstanding	45,606,651	36,936,560

*See accompanying notes.*





**MACROGENICS, INC.**  
**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**  
**(unaudited)**  
**(In thousands, except share amounts)**

	Common Stock			Additional	Accumulated	Accumulated	Total
	Share	Amount		Paid-In	Deficit	Other	Stockholders'
				Capital		Comprehensive	Equity
						Income	
Balance, December 31, 2018	42,353,301	424	\$ 732,727	\$ (490,271)	\$ (3)	\$ 242,877	
Share-based compensation	—	—	3,750	—	—	3,750	
Issuance of common stock, net of offering costs	6,326,300	—	118,594	—	—	118,657	
Stock plan related activity	126,707	—	346	—	—	347	
Unrealized gain on investments	—	—	—	—	3	3	
Net loss	—	—	—	(45,017)	—	(45,017)	
Balance, March 31, 2019	48,805,008	488	\$ 855,417	\$ (535,288)	\$ —	\$ 320,617	

	Common Stock			Additional	Accumulated	Accumulated	Total
	Share	Amount		Paid-In	Deficit	Other	Stockholders'
				Capital		Comprehensive	Equity
						Income	
Balance, December 31, 2017	36,859,077	369	\$ 611,270	\$ (312,340)	\$ (61)	\$ 299,238	
Cumulative effect of adoption of accounting	—	—	—	(6,479)	—	(6,479)	

Edgar Filing: MACROGENICS INC - Form 10-Q

standards					
Share-based compensation	—	3,386	—	—	3,386
Stock plan related activity	165,546	628	—	—	629
Unrealized gain on investments	—	—	—	38	38
Balance, Net loss	—	—	(49,536)	—	(49,536)
Balance, March 31, 2018	37,084,623	370	\$ 615,284	\$ (368,355)	\$ (23) \$ 247,276

*See accompanying notes.*

3

---

**MACROGENICS, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(unaudited)**  
**(in thousands)**

	<b>Three Months Ended March 31,</b>	
	<b>2019</b>	<b>2018</b>
<b>Cash flows from operating activities</b>		
Net loss	\$ (45,017)	\$ (49,536)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization expense	2,903	1,338
Stock-based compensation	3,799	3,432
Changes in operating assets and liabilities:		
Accounts receivable	23,468	6,361
Prepaid expenses	(1,902)	(177)
Other assets	(2,079)	40
Accounts payable and other liabilities	(2,531)	7,815
Accrued expenses	(4,297)	1,477
Lease exit liability	—	(298)
Lease liabilities	1,086	—
Deferred revenue	(5,430)	(1,435)
Deferred rent	—	(312)
Net cash used in operating activities	(30,000)	(31,295)

**Cash flows  
from investing  
activities**

Purchases of marketable securities	(81,597)	(24,452)
------------------------------------	----------	----------

Proceeds from sale and maturities of marketable securities	12,780	58,358
--	--------	--------

Purchases of property and equipment	(1,675)	(14,519)
-------------------------------------	---------	----------

Net cash provided by (used in) investing activities	(70,492)	19,387
---	----------	--------

**Cash flows  
from financing  
activities**

Proceeds from issuance of common stock, net of offering costs	118,657	—
---	---------	---

Proceeds from stock option exercises	348	629
--------------------------------------	-----	-----

Net cash provided by financing activities	119,005	629
---	---------	-----

Net change in cash and cash equivalents	18,513	(11,279)
---	--------	----------

Cash and cash equivalents at beginning of period	220,128	211,727
--	---------	---------

Cash and cash equivalents at end of period	\$ 238,641	\$ 200,448
--	------------	------------

**Supplemental  
cash flow  
information**

Right-of-use assets modified in exchange for \$	1,988	\$	—
operating lease obligations			

*See accompanying notes.*

4

---

**MACROGENICS, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)**

**1. Basis of Presentation and Significant Accounting Policies**

*Basis of Presentation*

The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.

The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2018 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2019.

*Summary of Significant Accounting Policies*

With the exception of the adoption of Accounting Standards Update (ASU) No. 2016-02, *Leases* (ASU 2016-02) during the three months ended March 31, 2019, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2018.

*Recent Accounting Pronouncements*

Recently Adopted Accounting Standards

In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet.

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets.

As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of \$16.4 million and operating lease liabilities of \$27.7 million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets. Refer to Note 4, Leases, for additional disclosures required by ASC 842.

Recently Issued Accounting Standards

In November 2018, the FASB issued ASU 2018-18, *Collaborative Arrangements (Topic 808)—Clarifying the interaction between Topic 808 and Topic 606* (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also

5

---



specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.

The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.

## 2. Fair Value of Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued expenses and common stock warrants. The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature. The Company accounts for recurring and non-recurring fair value measurements in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) 820, *Fair Value Measurements and Disclosures* (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

- Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
- Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
- Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.

Financial assets measured at fair value on a recurring basis were as follows (in thousands):

### Fair Value Measurements at March 31, 2019

	Total	Quoted Prices in Active Markets for Identical Assets			Significant Unobservable Inputs
		Level 1	Level 2	Level 3	
Assets:					
Money market funds	\$ 53,158	\$ 53,158	\$ —	\$ —	
Government-sponsored enterprises	17,389	—	17,389	—	
Corporate debt securities	89,424	—	89,424	—	
Common stock warrants	2,708	—	—	2,708	
	\$ 162,679	\$ 53,158	\$ 106,813	\$ 2,708	

Total assets measured  
at fair value<sup>(a)</sup>

6

---

**Fair Value Measurements at December 31, 2018**

		<b>Quoted Prices in Active Markets for Identical Assets</b>	<b>Significant Other Observable Inputs</b>	<b>Significant Unobservable Inputs</b>
	<b>Total</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Assets:				
Money market funds	\$ 46,257	\$ 46,257	\$ —	\$ —
U.S. Treasury securities	12,488	—	12,488	—
Corporate debt securities	100,214	—	100,214	—
Common stock warrants	1,890	—	—	1,890
Total assets measured at fair value <sup>(b)</sup>	\$ 160,849	\$ 46,257	\$ 112,702	\$ 1,890

(a) Total assets measured at fair value at March 31, 2019 includes approximately \$78.2 million reported in cash and cash equivalents and \$2.7 million reported in other assets on the balance sheet.

(b) Total assets measured at fair value at December 31, 2018 includes approximately \$146.2 million reported in cash and cash equivalents on the balance sheet and \$1.9 million reported in other assets on the balance sheet.

The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model. There were no transfers between levels during the periods presented.

**3. Marketable Securities**

Available-for-sale marketable securities as of March 31, 2019 and December 31, 2018 were as follows (in thousands):

	<b>March 31, 2019</b>			
	<b>Amortized Cost</b>	<b>Gross Unrealized Gains</b>	<b>Gross Unrealized Losses</b>	<b>Fair Value</b>
U.S. Treasury securities	\$ —	\$ —	\$ —	\$ —
Government-sponsored enterprises	17,389	1	—	17,390
Corporate debt securities	64,361	5	(6)	64,360
Total	\$ 81,750	\$ 6	\$ (6)	\$ 81,750

**December 31, 2018**

	<b>Amortized Cost</b>	<b>Gross Unrealized Gains</b>	<b>Gross Unrealized Losses</b>	<b>Fair Value</b>
Corporate debt securities	\$ 12,738	\$ —	\$ (3)	\$ 12,735

All available-for-sale marketable securities held as of March 31, 2019 and December 31, 2018 had contractual maturities of less than one year. All of the Company's available-for-sale marketable securities in an unrealized loss position as of March 31, 2019 and December 31, 2018 were in a loss position for less than 12 months. There were no unrealized losses at March 31, 2019 or December 31, 2018 that the Company determined to be other-than-temporary.

**4. Leases**

The Company has five non-cancelable operating leases for manufacturing, laboratory and office space in Rockville, Maryland and one non-cancelable operating lease for laboratory and office space in Brisbane, California. A portion of the space under one of these leases is subleased to a third party. All of these leases include one or more options to renew, with those

7

renewal periods ranging from five to 14 years. At March 31, 2019, the Company's weighted-average remaining lease term relating to its operating leases is 7 years, with a weighted-average discount rate of 9.9%.

Upon adoption of ASC 842 on January 1, 2019, it was not reasonably certain that the Company would extend any of the operating leases, therefore the options to extend the lease terms were not recognized as part of the ROU assets or lease liabilities. During the three months ended March 31, 2019, the Company determined that it would exercise the option to extend one lease for an additional five years, therefore the Company remeasured the lease liability and adjusted the carrying amount of the ROU asset related to this lease. The Company made cash payments of \$1.6 million for operating leases during the three months ended March 31, 2019. As of March 31, 2019, the Company's ROU assets were valued at \$17.7 million and are included in Other assets on the consolidated balance sheet. The components of lease cost for the three months ended March 31, 2019 were as follows (in thousands):

Operating lease cost	\$	1,341
Variable lease cost		236
Sublease income		(235)
Net lease cost	\$	1,342

As of March 31, 2019, the maturities of our operating lease liabilities were as follows (in thousands):

Remainder of 2019	\$	4,797
2020		5,634
2021		5,322
2022		5,468
2023		5,279
2024		4,293
Thereafter		10,081
Total lease payments		40,874
Present value adjustment		(12,097)
Lease liabilities	\$	28,777

## 5. Stockholders' Equity

In April 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold 4,500,000 shares of its common stock at a price of \$21.25 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 675,000 shares of the Company's common stock at a price of \$21.25 per share. Upon closing, the Company received net proceeds of approximately \$103.0 million from this offering, net of underwriting discounts and commissions and other offering expenses.

In February 2019, the Company completed a firm-commitment underwritten public offering, in which the Company sold 5,500,000 shares of its common stock at a price of \$20.00 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 825,000 shares of the Company's common stock at a price of \$20.00 per share. The Company received net proceeds of approximately \$118.7 million from this offering, net of underwriting discounts and commissions and other offering expenses.

## **6. Collaboration and Other Agreements**

### ***Incyte***

In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012 (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the

8

---

development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012. The Company received a \$150.0 million upfront payment from Incyte when the transaction closed in 2017.

Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately \$420.0 million in development and regulatory milestones and up to \$330.0 million in commercial milestones. As of March 31, 2019, the Company has recognized \$15.0 million in development milestones under this agreement. If MGA012 is commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities.

The Company evaluated the Incyte Agreement under the provisions of ASU No. 2014-09, *Revenue from Contracts with Customers* and all related amendments (collectively, ASC 606) and identified the following two performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte Agreement at inception was \$154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. During the three months ended March 31, 2019 and 2018, there were no adjustments to the transaction price of the Incyte Agreement.

The Company recognized the \$150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The \$4.0 million allocated to the clinical activities was recognized over the period from the effective date of the agreement until such time as the clinical activities were transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs. These clinical activities were substantially completed as of June 30, 2018. The Company recognized revenue of \$0.1 million and \$2.5 million under the Incyte Agreement during the three months ended March 31, 2019 and 2018, respectively.

The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte's clinical needs of MGA012. The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the clinical supply of MGA012. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. During the three months ended March 31, 2019, the Company

recognized revenue of \$4.0 million for services performed under this agreement. No revenue was recognized during the three months ended March 31, 2018 for services performed under this agreement.

***Les Laboratoires Servier***

In September 2012, the Company entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico,

9

---



Japan, South Korea and India (Servier Agreement). In 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab. In 2016, Servier notified the Company that it did not intend to exercise the option for the third DART molecule, and in November 2018, Servier notified the Company that it did not intend to exercise the option for MGD007.

Upon execution of the agreement, Servier made a nonrefundable payment of \$20.0 million to the Company. In addition, if Servier successfully develops, obtains regulatory approval for, and commercializes flotetuzumab, the Company will be eligible to receive up to \$22.5 million in clinical milestone payments, \$76.0 million in regulatory milestone payments and \$210.0 million in sales milestone payments. The Company and Servier will share Phase 2 and Phase 3 development costs. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.

The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options. The Company identified the following material promises under the arrangement for each of the three molecules: (i) a limited evaluation license to conduct activities under the research plan and (ii) research and development services concluding with an option trigger data package. The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights. As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule.

The Company determined that the \$20.0 million upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. Two milestones were achieved in 2014 when the Investigational New Drug (IND) applications for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA). Upon achievement of each milestone, the constraint related to the \$5.0 million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.

Revenue associated with each performance obligation was recognized as the research and development services were provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurred over this time period and, in management's judgment, was the best measure of progress towards satisfying the performance obligation. All revenue related to the upfront payment was recognized by December 31, 2018. The Company recognized no revenue during the three months ended March 31, 2019 related to the upfront payment and recognized \$0.5 million in revenue during the three months ended March 31, 2018 related to the transaction price allocated to the MGD007 option. No revenue was deferred at December 31, 2018 or March 31, 2019.

As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a \$15.0 million license grant fee. Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii) participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808, *Collaborative Arrangements* (ASC 808). The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan. Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the

license. The Company evaluated its performance obligation to provide Servier with an exclusive license to develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of \$15.0 million and Servier consumes the benefits of the license over time as the research and development activities are performed. Therefore, the Company will recognize the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and

---

development costs. The additional potential clinical, regulatory and sales milestones are fully constrained and have been excluded from the transaction price.

The Company recognized revenue related to the flotetuzumab license grant fee of \$0.2 million and \$0.3 million during the three months ended March 31, 2019 and 2018, respectively. At March 31, 2019, \$12.3 million of revenue related to the flotetuzumab license grant fee was deferred, \$1.3 million of which was current and \$11.0 million of which was non-current. At December 31, 2018, \$12.6 million of revenue related to the flotetuzumab license grant fee was deferred, \$0.9 million of which was current and \$11.7 million of which was non-current.

The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company follows its policy to record expense incurred as research and development expense and reimbursements received from Servier are recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period. During the three months ended March 31, 2019 and 2018, the Company recorded approximately \$0.8 million and \$1.2 million, respectively, as an offset to research and development expense under this collaborative arrangement.

#### ***Zai Lab***

In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory.

Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of \$25.0 million, less foreign withholding tax of \$2.5 million, which was received in January 2019. Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, the Company could receive up to \$140.0 million in development and regulatory milestones. In addition, Zai Lab would pay the Company double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.

The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and MGD013: (i) an exclusive license to develop and commercialize the product candidate in Zai Lab's territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and MGD013 are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the \$25.0 million (less foreign withholding tax of \$2.5 million) upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of each performance obligation was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.

Due to the relatively short-term nature of the recognition period, the revenue associated with the MGD013 performance obligation is being recognized on a straight-line basis as the Company performs research and

development activities under the agreement. The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements. During the three months ended March 31, 2019, the Company recognized revenue of \$4.0 million related to the Zai Lab Agreement. At March 31, 2019, \$17.1 million of revenue was deferred under this

11

---

agreement, \$12.1 million of which was current and \$5.0 million of which was non-current. At December 31, 2018, \$21.1 million of revenue was deferred under this agreement, \$16.1 million of which was current and \$5.0 million of which was non-current.

### ***Roche***

In December 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets (Roche Agreement). During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies, to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate. Each company will be responsible for its own expenses during the research period.

Under the terms of the Roche Agreement, Roche received rights to use certain of the Company's intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of \$10.0 million which was received in January 2018. The Company will also be eligible to receive up to \$370.0 million in potential milestone payments and royalties on future sales. As of March 31, 2019, the Company has not recognized any milestone revenue under this agreement.

The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period. The Company determined that the license is capable of being distinct, but is not distinct in the context of the contract because it has limited value to Roche without the research activities required to be performed by the Company. Therefore, the Company concluded that there is one performance obligation under the agreement. The Company determined that the transaction price of the Roche Agreement was \$10.0 million. The potential milestone payments are fully constrained and have been excluded from the transaction price. Any consideration related to sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore have also been excluded from the transaction price.

The \$10.0 million transaction price is being recognized over the expected research period, which is 30 months, using a cost-based input method to measure performance. The Company recognized revenue under this agreement of \$1.0 million during each of the three month periods ended March 31, 2019 and 2018. At March 31, 2019, \$5.0 million of revenue was deferred under this agreement, \$4.0 million of which was current and \$1.0 million of which was non-current. At December 31, 2018, \$6.0 million of revenue was deferred under this agreement, \$4.0 million of which was current and \$2.0 million of which was non-current.

### ***Provention***

In May 2018, the Company entered into a License Agreement with Provention Bio, Inc. (Provention), pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention's common stock at an exercise price of \$2.50 per share. The warrant expires on May 7, 2025. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to \$65.0 million in development and regulatory milestones and up to \$225.0 million in commercial milestones. As of March 31, 2019, the Company has not recognized any milestone revenue under this agreement. If PRV-3279 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.

Also in May 2018, the Company entered into an Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company's interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Provention Asset Purchase Agreement). As partial consideration for the Provention Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention's common stock at an exercise price of \$2.50 per share. The warrant expires on May 7, 2025. If Provention

successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to \$170.0 million in regulatory milestones and up to \$225.0 million in commercial milestones. If PRV-031 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.

Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone

12

---

payments of up to approximately \$1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Provention Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party.

The Company evaluated the Provention License Agreement and Provention Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was \$6.1 million, based on the Black-Scholes valuation of the warrants to purchase 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant, which represents the relative fair value of each performance obligation. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.

The Company recognized revenue of \$6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention during May 2018. The warrants are reported in other assets on the consolidated balance sheet and are revalued at each reporting period based on current Black-Scholes parameters until exercised or the warrants lapse. The resulting increase or decrease is reflected in other income (expense) on the consolidated statement of operations and comprehensive loss. The warrants were valued at \$2.7 million and \$1.9 million as of March 31, 2019 and December 31, 2018, respectively.

#### ***NIAID Contract***

The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015, to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Agreement). Under the NIAID Agreement, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.

The NIAID Agreement includes a base period of up to \$7.5 million to support development of MGD014 through IND application submission with the FDA, as well as up to \$17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to \$24.5 million. The total potential period of performance under the award is from September 15, 2015 through September 14, 2022. In 2017, NIAID exercised the first option in the amount of up to \$10.8 million. The Company recognized \$0.2 million in revenue under the NIAID Agreement during each of the three month periods ended March 31, 2019 and 2018.

## **7. Stock-Based Compensation**

### ***Employee Stock Purchase Plan***

In May 2017, the Company's stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company's common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company's common stock on the last day of the offering period. During the three months ended March 31, 2019, no shares of common stock were purchased under the 2016 ESPP.

*Employee Stock Option Plans*

Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards

13

---



may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares. As of March 31, 2019, under the 2003 Plan, there were options to purchase an aggregate of 630,367 shares of common stock outstanding at a weighted average exercise price of \$2.19 per share.

In October 2013, the Company implemented the 2013 Plan. The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the three months ended March 31, 2019, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 9,938,263. If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of March 31, 2019, there were options to purchase an aggregate of 6,089,880 shares of common stock outstanding at a weighted average exercise price of \$24.58 per share under the 2013 Plan. The following stock-based compensation expense was recognized for the periods indicated (in thousands):

	<b>Three Months Ended March 31,</b>	
	<b>2019</b>	<b>2018</b>
Research and development	\$ 1,814	\$ 1,700
General and administrative	1,985	1,732
Total stock-based compensation expense	\$ 3,799	\$ 3,432

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:

	<b>Three Months Ended March 31,</b>	
	<b>2019</b>	<b>2018</b>
Expected dividend yield	—%	—%
Expected volatility	73.7% - 74.4%	68% - 71%
Risk-free interest rate	2.3% - 2.6%	2.4% - 2.8%

Expected term 6.25 years 6.25 years

The following table summarizes stock option activity during the three months ended March 31, 2019:

	<b>Shares</b>	<b>Weighted-Average Exercise Price</b>	<b>Weighted-Average Remaining Contractual Term (Years)</b>	<b>Aggregate Intrinsic Value (in thousands)</b>
Outstanding, December 31, 2018	5,273,964	\$ 22.23	6.8	
Granted	1,628,022	21.82		
Exercised	(126,707)	2.84		
Forfeited or expired	(55,032)	21.02		
Outstanding, March 31, 2019	6,720,247	22.48	7.4	\$ 10,712
As of March 31, 2019:				
Exercisable	3,593,089	21.44	5.9	10,670
Vested and expected to vest	6,407,781	22.41	7.4	10,707

The weighted-average grant-date fair value of options granted during the three months ended March 31, 2019 and 2018 was \$14.65 and \$18.75, respectively. The total intrinsic value of options exercised during the three months ended March 31, 2019 and 2018 was approximately \$1.6 million and \$3.6 million, respectively. The total cash received for options exercised during the three months ended March 31, 2019 and 2018 was approximately \$0.3 million and \$0.6 million,

14

---

respectively. The total fair value of shares vested in the three months ended March 31, 2019 and 2018 was approximately \$3.1 million and \$3.3 million, respectively. As of March 31, 2019, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was approximately \$42.0 million, which the Company expects to recognize over a weighted-average period of approximately 3.1 years.

**MANAGEMENT'S  
DISCUSSION AND  
ANALYSIS OF  
FINANCIAL  
CONDITION AND  
RESULTS OF  
OPERATIONS**

**ITEM  
2.**

*The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with U.S. Generally Accepted Accounting Principles (GAAP), for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.*

**Overview**

We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics to modulate the human immune response for the treatment of cancer. We currently have a pipeline of product candidates in human clinical testing that have been created primarily using our proprietary technology platforms. We believe our programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.

We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of March 31, 2019, as well as collaboration payments we anticipate receiving, will enable us to fund our operations into 2021 based on our current business plan.

Through March 31, 2019, we had an accumulated deficit of \$535.3 million. We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.

**Strategic Collaborations**

We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current strategic collaborations include the following:

- Incyte*. In October 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while we retain the right to develop our pipeline assets in combination with MGA012. The transaction closed in the fourth quarter of 2017 and we received a \$150.0 million upfront payment from Incyte upon the closing.

Under the terms of the collaboration, Incyte will lead global development of MGA012. Assuming successful development and commercialization of MGA012 by Incyte, we could receive development and regulatory milestones of up to approximately \$420.0 million, of which we have already received \$15.0 million, and up to \$330.0 million in

commercial milestones. If MGA012 is commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote with Incyte. We retain the right to develop our pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and MacroGenics commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of MGA012. In addition, we retain the right to manufacture a portion of both companies' global commercial supply needs of MGA012 subject to a separate commercial supply agreement.

16

---

•*Servier*. In September 2012, we entered into an agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) to develop and commercialize three DART molecules in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. In February 2014, Servier exercised its option to develop and commercialize flotetuzumab, for which we received a \$15.0 million license option fee. We received a \$20.0 million upfront option fee upon execution of the agreement. In addition, we will be eligible to receive up to approximately \$308.5 million in additional clinical, development, regulatory and sales milestone payments if Servier successfully develops, obtains regulatory approval for, and commercializes flotetuzumab. Servier may share Phase 2 and Phase 3 development costs and would be obligated to pay us low double-digit to mid-teen royalties on product sales in its territories. As of March 31, 2019, Servier had terminated its option to license MGD007 and the third DART molecule.

•*Zai Lab*. In November 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development in its territory. Under the terms of the agreement, Zai Lab paid us an upfront payment of \$25.0 million less foreign withholding tax of \$2.5 million, which was received in January 2019. Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, we could receive up to \$140.0 million in development and regulatory milestones. In addition, Zai Lab would pay us double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.

### Critical Accounting Policies and Significant Judgments and Estimates

Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2018. Except as described in Note 1 to our accompanying consolidated financial statements with respect to our adoption of the requirements of ASC 842, there have been no significant changes to our critical accounting policies and estimates during the three months ended March 31, 2019.

### Results of Operations

#### Revenue

The following represents a comparison of our revenue for the three months ended March 31, 2019 and 2018:

	Three Months Ended March 31,		Increase/(Decrease)	
	2019	2018		
	(dollars in millions)			
Revenue from collaborative agreements	\$ 9.5	\$ 4.5	\$ 5.0	100%
Revenue from government agreements	0.2	0.2	—	(0%)
<b>Total revenue</b>	<b>\$ 9.7</b>	<b>\$ 4.7</b>	<b>\$ 5.0</b>	<b>106%</b>

The increase of \$5.0 million in revenue from collaborative agreements for the three months ended March 31, 2019 compared to the three months ended March 31, 2018 was primarily due to:

- revenue recognized under the Incyte clinical supply agreement of \$4.0 million during the three months ended March 31, 2019; and
- revenue recognition of the deferred upfront payment under the Zai Lab collaboration and license agreement.

17

---

**Research and Development Expense**

The following represents a comparison of our research and development expense for the three months ended March 31, 2019 and 2018:

	Three Months Ended March 31,		Increase/(Decrease)	
	2019	2018		
	(dollars in millions)			
Margetuximab	\$ 13.0	\$ 18.5	\$ (5.5)	(30)
MGA012	8.2	7.4	0.8	1%
Enoblituzumab	3.1	4.8	(1.7)	(35)
Flotetuzumab (a)	3.5	2.1	1.4	6%
MGD013	3.9	1.1	2.8	25%
MGD019	1.1	1.0	0.1	1%
MGC018	3.3	1.6	1.7	10%
MGD007	1.1	1.9	(0.8)	(42)
MGD009	1.9	2.2	(0.3)	(14)
Other immune modulator programs	2.3	1.4	0.9	6%
Discovery and other pipeline programs, collectively	5.7	3.7	2.0	5%
<b>Total research and development expense</b>	<b>\$ 47.1</b>	<b>\$ 45.7</b>	<b>\$ 1.4</b>	<b>3%</b>

(a) Expenses are shown net of reimbursements from collaborator.

Our research and development expense for the three months ended March 31, 2019 increased by \$1.4 million compared to the three months ended March 31, 2018 primarily due to:

- increased development/manufacturing costs related to MGA012 (which are partially offset by revenue recognized under the Incyte clinical supply agreement);
- increased clinical trial costs related to continued enrollment in an additional cohort expansion of our Phase 1 flotetuzumab study;
- increased clinical trial costs related to our ongoing MGD013 Phase 1 study; and
- initiation of our MGC018 Phase 1 study.

These increases were partially offset by:

- decreased clinical trial costs due to completed enrollment in our margetuximab Phase 3 SOPHIA study; and
- decreased expenses from two enoblituzumab clinical trials.

**General and Administrative Expense**



The following represents a comparison of our general and administrative expense for the three months ended March 31, 2019 and 2018:

	<b>Three Months Ended March 31,</b>		<b>Increase</b>	
	<b>2019</b>	<b>2018</b>		
	<b>(dollars in millions)</b>			
General and administrative expense	\$ 10.2	\$ 9.2	\$ 1.0	1%

General and administrative expense increased for the three months ended March 31, 2019 compared to the three months ended March 31, 2018 primarily due to consulting expenses and other professional service fees.

**Other Income**

Other income increased by \$1.9 million for the three months ended March 31, 2019 compared to the three months ended March 31, 2018, due to an increase in interest income earned on investments and the revaluation at March 31, 2019 of the warrants received under the Provention License Agreement and Asset Purchase Agreement.

**Liquidity and Capital Resources**

We have historically financed our operations primarily through public and private offerings of equity, upfront fees, milestone payments and license option fees from collaborators and reimbursement through government grants and contracts. As of March 31, 2019, we had \$320.4 million in cash, cash equivalents and marketable securities. In addition to our existing cash, cash equivalents and marketable securities, we are eligible to receive additional reimbursement from our collaborators, including under various government grants or contracts, for certain research and development services rendered, additional milestone payments and opt-in payments. However, our ability to receive these milestone payments is dependent upon our ability to successfully complete specified research and development activities and is therefore uncertain at this time.

**Funding Requirements**

We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval for and commercialize one or more of our product candidates. As we are currently in the clinical trial stage of development, it will be some time before we expect to generate revenue from product sales and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as well as additional clinical trials and preclinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our existing cash, cash equivalents and marketable securities as of March 31, 2019, as well as collaboration payments we anticipate receiving, will enable us to fund our operations into 2021, assuming all of our programs and collaborations advance as currently contemplated.

**Cash Flows**

The following table represents a summary of our cash flows for the three months ended March 31, 2019 and 2018:

	<b>Three Months Ended</b>	
	<b>March 31,</b>	
	<b>2019</b>	<b>2018</b>
	<b>(dollars in millions)</b>	
<b>Net cash provided by (used in):</b>		
Operating activities	\$ (30.0)	\$ (31.3)
Investing activities	(70.5)	19.4
Financing activities	119.0	0.6
<b>Net change in cash and cash equivalents</b>	<b>\$ 18.5</b>	<b>\$ (11.3)</b>

*Operating Activities*

Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and preclinical activities. The principal use of cash in operating activities for all periods presented was to fund our net loss, adjusted for non-cash items, with the three months ended March 31, 2019 benefiting from the \$22.5 million upfront payment from Zai Lab and the three months ended March 31, 2018 benefiting from the \$10.0 million upfront payment from Roche.

*Investing Activities*

Net cash used in investing activities during the three months ended March 31, 2019 is primarily due to purchases of marketable securities partially offset by sales of marketable securities. Net cash provided by investing activities during the three months ended March 31, 2018 is primarily due to maturities of marketable securities partially offset by purchases of marketable securities and making significant leasehold improvements to our facilities, including the build-out of our manufacturing suite at our headquarters location.

19

---

*Financing Activities*

Net cash provided by financing activities for the three months ended March 31, 2019 is primarily due to the proceeds from our firm-commitment underwritten public offering, which closed in February 2019. Net cash provided by financing activities for the three months ended March 31, 2018 is primarily due to cash from stock option exercises.

**Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission (SEC).

20

---

**QUANTITATIVE  
AND  
ITEM 3. QUALITATIVE  
DISCLOSURES  
ABOUT MARKET  
RISK**

Our primary objective when considering our investment activities is to preserve capital in order to fund our operations. We also seek to maximize income from our investments without assuming significant risk. Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments. As of March 31, 2019, we had cash, cash equivalents and marketable securities of \$320.4 million. Our primary exposure to market risk is related to changes in interest rates. Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.

**ITEM 4. CONTROLS  
AND  
PROCEDURES**

**Disclosure Controls and Procedures**

Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2019. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of March 31, 2019, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.

**Changes in Internal Control**

There were no changes in the Company's internal control over financial reporting that occurred during the three months ended March 31, 2019 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.

**PART II. OTHER INFORMATION**

**Item Risk  
1A. Factors**

Our material risk factors are disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

**Item 6. Exhibits**

- 31.1 Rule 13a-14(a) Certification of Principal Executive Officer
- 31.2 Rule 13a-14(a) Certification of Principal Financial Officer
- 32.1 Section 1350 Certification of Principal Executive Officer
- 32.2 Section 1350 Certification of Principal Financial Officer
- 101.INS XBRL Instance Document
- 101.SCH XBRL Schema Document
- 101.CAL XBRL Calculation Linkbase Document
- 101.DEF XBRL Definition Linkbase Document
- 101.LAB XBRL Labels Linkbase Document
- 101.PRE XBRL Presentation Linkbase

Document

22

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MACROGENICS,  
INC.

BY: /s/ Scott  
Koenig  
Scott  
Koenig,  
M.D., Ph.D.  
President  
and Chief  
Executive  
Officer  
(Principal  
Executive  
Officer)

BY: /s/ James  
Karrels  
James  
Karrels  
Senior Vice  
President  
and Chief  
Financial  
Officer  
(Principal  
Financial  
Officer)

Dated:  
May 1,  
2019



EXHIBIT INDEX

Exhibit Page Number

31.1	<u>Rule</u> <u>13a-14(a)</u> <u>Certification</u> <u>of Principal</u> <u>Executive</u> <u>Officer</u>
31.2	<u>Rule</u> <u>13a-14(a)</u> <u>Certification</u> <u>of Principal</u> <u>Financial</u> <u>Officer</u>
32.1	<u>Section 1350</u> <u>Certification</u> <u>of Principal</u> <u>Executive</u> <u>Officer</u>
32.2	<u>Section 1350</u> <u>Certification</u> <u>of Principal</u> <u>Financial</u> <u>Officer</u>
101.INS	XBRL Instance Document
101.SCH	XBRL Schema Document
101.CAL	XBRL Calculation Linkbase Document
101.DEF	XBRL Definition Linkbase Document
101.LAB	XBRL Labels Linkbase Document
101.PRE	XBRL Presentation Linkbase Document

